Pittsburgh, Pennsylvania
Cancer biologic therapy trials in Pittsburgh, PA
48 cancer biologic therapy studies are recruiting participants at sites in Pittsburgh as of November 18, 2026, according to ClinicalTrials.gov. Cancer Biologic Trials can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Pittsburgh at a glance
- 48 studies are recruiting at a site in Pittsburgh.
- By phase: Early Phase 1 (1), Phase 1 (6), Phase 1/2 (11), Phase 2 (14), Phase 2/3 (2), Phase 3 (14).
- By sponsor: industry (18), government (15), university, hospital or other (15).
- By research area: Lung Cancer (15), Breast Cancer (10), Melanoma (10), Lymphoma (9), Prostate Cancer (3), Pancreatic Cancer (1).
- Most recent update to one of these records: November 18, 2026.
Breast cancer studies recruiting in Pittsburgh
Basic details from each study's public record (the 30 most recently updated of 48). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- UPMC Hillman Cancer Center
- Registry record
- NCT03606967 · updated
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Phase 2
- All ages
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- UPMC Hillman Cancer Center · UPMC-Magee Womens Hospital · UPMC-Passavant Hospital
- Registry record
- NCT05564377 · updated
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Allegheny General Hospital · UPMC Hillman Cancer Center · UPMC-Magee Womens Hospital
- Registry record
- NCT06058377 · updated
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- University of Pittsburgh Medical Center Magee-Womens Hospital ( Site 0058)
- Registry record
- NCT07060807 · updated
Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ
- Phase 1
- Ages 18 and older
- Female participants
- Sponsor
- Finn, Olivera, PhD
- Study site
- UPMC Magee Womens Hospital
- Registry record
- NCT06218303 · updated
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study sites
- Allegheny General Hospital · UPMC Hillman Cancer Center · UPMC-Magee Womens Hospital
- Registry record
- NCT06876714 · updated
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- AstraZeneca
- Registry record
- NCT05877599 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Pittsburgh, PA on ClinicalTrials.gov.
Lung cancer studies recruiting in Pittsburgh
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- UPMC Hillman Cancer Center
- Registry record
- NCT06498635 · updated
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Summit Therapeutics
- Registry record
- NCT06767514 · updated
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- UPMC Hillman Cancer Center
- Registry record
- NCT06287775 · updated
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- UPMC Hillman Cancer Center · UPMC-Mercy Hospital · UPMC-Passavant Hospital
- Registry record
- NCT04267848 · updated
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Obsidian Therapeutics, Inc.
- Study site
- Allegheny Research Institute (Melanoma/NSCLC)
- Registry record
- NCT06060613 · updated
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Olivera Finn
- Study site
- UPMC Hillman Cancer Center
- Registry record
- NCT01720836 · updated
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- Phase 2
- From 18 minutes
- All sexes
- Sponsor
- SWOG Cancer Research Network
- Study site
- UPMC Hillman Cancer Center
- Registry record
- NCT06031688 · updated
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- SWOG Cancer Research Network
- Study sites
- UPMC Hillman Cancer Center · UPMC-Passavant Hospital · UPMC-Saint Margaret
- Registry record
- NCT06116682 · updated
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- Phase 2/3
- Ages 18 and older
- All sexes
- Sponsor
- SWOG Cancer Research Network
- Study sites
- UPMC Hillman Cancer Center · UPMC-Passavant Hospital · UPMC-Saint Clair Hospital Cancer Center
- Registry record
- NCT06616584 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Pittsburgh, PA on ClinicalTrials.gov.
Prostate cancer studies recruiting in Pittsburgh
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- UPMC Hillman Cancer Center · UPMC-Passavant Hospital · UPMC-Saint Clair Hospital Cancer Center
- Registry record
- NCT03866382 · updated
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Phase 3
- Ages 18 and older
- Male participants
- Sponsor
- Janssen Research & Development, LLC
- Study site
- UPMC Cancer Centers
- Registry record
- NCT07164443 · updated
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- Phase 1
- Ages 18 to 100
- Male participants
- Sponsor
- Janux Therapeutics
- Study site
- UPMC Hillman Cancer Center
- Registry record
- NCT05519449 · updated
Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Pittsburgh, PA on ClinicalTrials.gov.
Melanoma studies recruiting in Pittsburgh
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Immatics US, Inc.
- Study site
- UPMC Hillman Cancer Center
- Registry record
- NCT06743126 · updated
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- UPMC Hillman Cancer Center
- Registry record
- NCT05896839 · updated
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
- Phase 3
- Ages 18 to 70
- All sexes
- Sponsor
- Iovance Biotherapeutics, Inc.
- Study site
- Allegheny Health Network
- Registry record
- NCT05727904 · updated
Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Pittsburgh, PA on ClinicalTrials.gov.
Lymphoma studies recruiting in Pittsburgh
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Phase 2
- Up to 365 days
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Children's Hospital of Pittsburgh of UPMC
- Registry record
- NCT06317662 · updated
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Phase 2
- Ages 1 to 30
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Children's Hospital of Pittsburgh of UPMC
- Registry record
- NCT04546399 · updated
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- Phase 3
- Ages 5 to 60
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Children's Hospital of Pittsburgh of UPMC
- Registry record
- NCT05675410 · updated
Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- UPMC Hillman Cancer Center
- Registry record
- NCT07003295 · updated
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Allogene Therapeutics
- Study site
- West Penn Hospital
- Registry record
- NCT06500273 · updated
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Phase 2
- From 366 days, up to 46 years
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Children's Hospital of Pittsburgh of UPMC
- Registry record
- NCT06124157 · updated
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
- Phase 2
- Ages 1 to 60
- All sexes
- Sponsor
- Fred Hutchinson Cancer Center
- Study site
- University of Pittsburgh Cancer Institute (UPCI)
- Registry record
- NCT03970096 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Pittsburgh, PA on ClinicalTrials.gov.
Pancreatic cancer studies recruiting in Pittsburgh
Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- UPMC Hillman Cancer Center
- Registry record
- NCT07619521 · updated
Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Pittsburgh, PA on ClinicalTrials.gov.
Ask about studies near Pittsburgh
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
More locations in Pennsylvania
All Pennsylvania locations
97 studies recruiting across 68 cities.
Philadelphia
60 studies recruiting.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a biologic, such as a vaccine, an antibody, or a cell or gene therapy, as each study is coded in the registry.
Cancer Biologic Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections